{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:45:54Z","timestamp":1790401554255,"version":"4.1.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T00:00:00Z","timestamp":1619222400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP 1184344"],"award-info":[{"award-number":["OPP 1184344"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R015600\/1"],"award-info":[{"award-number":["MR\/R015600\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UK Department for International Development"},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Drug-based interventions are at the heart of global efforts to reach elimination as a public health problem (trachoma, soil-transmitted helminthiases, schistosomiasis, lymphatic filariasis) or elimination of transmission (onchocerciasis) for 5 of the most prevalent neglected tropical diseases tackled via the World Health Organization preventive chemotherapy strategy. While for some of these diseases there is optimism that currently available drugs will be sufficient to achieve the proposed elimination goals, for others\u2014particularly onchocerciasis\u2014there is a growing consensus that novel therapeutic options will be needed. Since in this area no high return of investment is possible, minimizing wasted money and resources is essential. Here, we use illustrative results to show how mathematical modeling can guide the drug development pathway, yielding resource-saving and efficiency payoffs, from the refinement of target product profiles and intended context of use to the design of clinical trials.<\/jats:p>","DOI":"10.1093\/cid\/ciab350","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T16:14:33Z","timestamp":1619108073000},"page":"e1391-e1396","source":"Crossref","is-referenced-by-count":10,"title":["Supporting Drug Development for Neglected Tropical Diseases Using Mathematical Modeling"],"prefix":"10.1093","volume":"73","author":[{"given":"Martin","family":"Walker","sequence":"first","affiliation":[{"name":"Department of Pathobiology and Population Sciences and London Centre for Neglected Tropical Disease Research, Royal Veterinary College, Hatfield, United Kingdom"},{"name":"MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology and London Centre for Neglected Tropical Disease Research, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I D","family":"Hamley","sequence":"additional","affiliation":[{"name":"MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology and London Centre for Neglected Tropical Disease Research, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Milton","sequence":"additional","affiliation":[{"name":"MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology and London Centre for Neglected Tropical Disease Research, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Monnot","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Kinrade","sequence":"additional","affiliation":[{"name":"Medicines Development for Global Health, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Specht","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9len","family":"Pedrique","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Gloria","family":"Bas\u00e1\u00f1ez","sequence":"additional","affiliation":[{"name":"MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology and London Centre for Neglected Tropical Disease Research, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,23]]},"reference":[{"key":"2021091515515813900_CIT0001","volume-title":"Crossing the billion. Lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminthiases and trachoma. Preventive chemotherapy for neglected tropical diseases","author":"World Health Organization","year":"2017"},{"key":"2021091515515813900_CIT0002","volume-title":"Ending the neglect to attain the Sustainable Development Goals. A road map for neglected tropical diseases 2021\u20132030","author":"World Health Organization","year":"2020"},{"key":"2021091515515813900_CIT0003","doi-asserted-by":"crossref","first-page":"j4307","DOI":"10.1136\/bmj.j4307","article-title":"Efficacy of recommended drugs against soil transmitted helminths: systematic review and network meta-analysis","volume":"358","author":"Moser","year":"2017","journal-title":"BMJ"},{"key":"2021091515515813900_CIT0004","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.12688\/gatesopenres.13077.2","article-title":"Insights from quantitative analysis and mathematical modelling on the proposed WHO 2030 goals for soil-transmitted helminths","volume":"3","author":"NTD Modelling Consortium Discussion Group on Soil-Transmitted Helminths","year":"2019","journal-title":"Gates Open Res"},{"key":"2021091515515813900_CIT0005","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.12688\/gatesopenres.13052.1","article-title":"Insights from quantitative and mathematical modelling on the proposed WHO 2030 goal for schistosomiasis","volume":"3","author":"NTD Modelling Consortium Schistosomiasis Group","year":"2019","journal-title":"Gates Open Res"},{"key":"2021091515515813900_CIT0006","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.12688\/gatesopenres.13086.1","article-title":"Insights from mathematical modelling and quantitative analysis on the proposed 2030 goals for trachoma","volume":"3","author":"NTD Modelling Consortium Discussion Group on Trachoma.","year":"2019","journal-title":"Gates Open Res"},{"key":"2021091515515813900_CIT0007","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S1473-3099(05)70192-4","article-title":"Mass chemotherapy options to control lymphatic filariasis: a systematic review","volume":"5","author":"Tisch","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"2021091515515813900_CIT0008","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1706854","article-title":"A trial of a triple-drug treatment for lymphatic filariasis","volume":"379","author":"King","year":"2018","journal-title":"N Engl J Med"},{"key":"2021091515515813900_CIT0009","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1473-3099(17)30175-5","article-title":"Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo","volume":"17","author":"Pion","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2021091515515813900_CIT0010","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.12688\/gatesopenres.13065.1","article-title":"The roadmap towards elimination of lymphatic filariasis by 2030: insights from quantitative and mathematical modelling","volume":"3","author":"NTD Modelling Consortium Lymphatic Filariasis Group","year":"2019","journal-title":"Gates Open Res"},{"key":"2021091515515813900_CIT0011","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1473-3099(08)70099-9","article-title":"Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis","volume":"8","author":"Bas\u00e1\u00f1ez","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"2021091515515813900_CIT0012","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/cid\/ciw144","article-title":"Does increasing treatment frequency address suboptimal responses to ivermectin for the control and elimination of river blindness?","volume":"62","author":"Frempong","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021091515515813900_CIT0013","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1093\/cid\/cix616","article-title":"Macrofilaricidal efficacy of repeated doses of ivermectin for the treatment of river blindness","volume":"65","author":"Walker","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021091515515813900_CIT0014","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/cid\/cix1137","article-title":"How can onchocerciasis elimination in africa be accelerated? Modeling the impact of increased ivermectin treatment frequency and complementary vector control","volume":"66","author":"Verver","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2021091515515813900_CIT0015","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.12688\/gatesopenres.13067.1","article-title":"The World Health Organization 2030 goals for onchocerciasis: insights and perspectives from mathematical modelling","volume":"3","author":"NTD Modelling Consortium Onchocerciasis Group.","year":"2019","journal-title":"Gates Open Res"},{"key":"2021091515515813900_CIT0016","doi-asserted-by":"crossref","first-page":"e0004328","DOI":"10.1371\/journal.pntd.0004328","article-title":"Model-based geostatistical mapping of the prevalence of Onchocerca volvulus in West Africa","volume":"10","author":"O\u2019Hanlon","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"2021091515515813900_CIT0017","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s40249-018-0446-z","article-title":"Is onchocerciasis elimination in Africa feasible by 2025: a perspective based on lessons learnt from the African control programmes","volume":"7","author":"Dadzie","year":"2018","journal-title":"Infect Dis Poverty"},{"key":"2021091515515813900_CIT0018","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/14787210.2020.1792772","article-title":"Moxidectin: an oral treatment for human onchocerciasis","volume":"18","author":"Milton","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2021091515515813900_CIT0019","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0140-6736(17)32844-1","article-title":"Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial","volume":"392","author":"Opoku","year":"2018","journal-title":"Lancet"},{"key":"2021091515515813900_CIT0020","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13071-015-0779-4","article-title":"The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data","volume":"8","author":"Turner","year":"2015","journal-title":"Parasit Vectors"},{"key":"2021091515515813900_CIT0021","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/S0140-6736(18)30101-6","article-title":"A new powerful drug to combat river blindness","volume":"392","author":"Boussinesq","year":"2018","journal-title":"Lancet"},{"key":"2021091515515813900_CIT0022","doi-asserted-by":"crossref","first-page":"e1210","DOI":"10.1371\/journal.pntd.0001210","article-title":"The geographic distribution of Loa loa in Africa: results of large-scale implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA)","volume":"5","author":"Zour\u00e9","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"2021091515515813900_CIT0023","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1371\/journal.pntd.0000660","article-title":"Macrofilaricidal activity after doxycycline only treatment of Onchocerca volvulus in an area of Loa loa co-endemicity: a randomized controlled trial","volume":"4","author":"Turner","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"2021091515515813900_CIT0024","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1756-3305-2-39","article-title":"Community-directed delivery of doxycycline for the treatment of onchocerciasis in areas of co-endemicity with loiasis in Cameroon","volume":"2","author":"Wanji","year":"2009","journal-title":"Parasit Vectors"},{"key":"2021091515515813900_CIT0025","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau2086","article-title":"Preclinical development of an oral anti-Wolbachia macrolide drug for the treatment of lymphatic filariasis and onchocerciasis","volume":"11","author":"Taylor","year":"2019","journal-title":"Sci Transl Med"},{"key":"2021091515515813900_CIT0026","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/cid\/ciu1152","article-title":"Therapeutic efficacy and macrofilaricidal activity of doxycycline for the treatment of river blindness","volume":"60","author":"Walker","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2021091515515813900_CIT0027","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1473-3099(16)30467-4","article-title":"Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study","volume":"17","author":"Irvine","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2021091515515813900_CIT0028","doi-asserted-by":"crossref","first-page":"e0005163","DOI":"10.1371\/journal.pntd.0005163","article-title":"Potential value of triple drug therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) to accelerate elimination of lymphatic filariasis and onchocerciasis in Africa","volume":"11","author":"Fischer","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"2021091515515813900_CIT0029","first-page":"96","article-title":"Efficacy of anthelminthic drugs and drug combinations against soil-transmitted helminths: a systematic review and network meta-analysis","volume":"68","author":"Clarke","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021091515515813900_CIT0030","first-page":"1193","article-title":"Efficacy and safety of ascending dosages of moxidectin and moxidectin-albendazole against Trichuris trichiura in adolescents: a randomized controlled trial","volume":"70","author":"Keller","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021091515515813900_CIT0031","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijpddr.2016.04.002","article-title":"Research for new drugs for elimination of onchocerciasis in Africa","volume":"6","author":"Kuesel","year":"2016","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"2021091515515813900_CIT0032","first-page":"1151","article-title":"Reduced efficacy of praziquantel against Schistosoma mansoni is associated with multiple rounds of mass drug administration","volume":"63","author":"Crellen","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021091515515813900_CIT0033","author":"Uniting to Combat Neglected Tropical Diseases."},{"key":"2021091515515813900_CIT0034","author":"US Food and Drug Administration"},{"key":"2021091515515813900_CIT0035","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1016\/S2214-109X(13)70078-0","article-title":"The drug and vaccine landscape for neglected diseases (2000-11): a systematic assessment","volume":"1","author":"Pedrique","year":"2013","journal-title":"Lancet Glob Health"},{"key":"2021091515515813900_CIT0036","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1038\/s41467-020-16442-y","article-title":"Designing antifilarial drug trials using clinical trial simulators","volume":"11","author":"Walker","year":"2020","journal-title":"Nat Commun"},{"key":"2021091515515813900_CIT0037","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/bcp.12341","article-title":"Model-based clinical drug development in the past, present and future: a commentary","volume":"79","author":"Kimko","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"2021091515515813900_CIT0038","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41598-017-00322-5","article-title":"Short-course, high-dose rifampicin achieves Wolbachia depletion predictive of curative outcomes in preclinical models of lymphatic filariasis and onchocerciasis","volume":"7","author":"Aljayyoussi","year":"2017","journal-title":"Sci Rep"},{"key":"2021091515515813900_CIT0039","doi-asserted-by":"crossref","first-page":"e0007557","DOI":"10.1371\/journal.pntd.0007557","article-title":"Modelling exposure heterogeneity and density dependence in onchocerciasis using a novel individual-based transmission model, EPIONCHO-IBM: implications for elimination and data needs","volume":"13","author":"Hamley","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"2021091515515813900_CIT0040","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1086\/383326","article-title":"Incidence of blindness during the Onchocerciasis Control Programme in western Africa, 1971\u20132002","volume":"189","author":"Little","year":"2004","journal-title":"J Infect Dis"},{"key":"2021091515515813900_CIT0041","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1179\/000349802125000826","article-title":"Onchocerciasis: the clinical and epidemiological burden of skin disease in Africa","volume":"96","author":"Murdoch","year":"2002","journal-title":"Ann Trop Med Parasitol"},{"key":"2021091515515813900_CIT0042","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.parepi.2016.02.004","article-title":"Analysis of the population-level impact of co-administering ivermectin with albendazole or mebendazole for the control and elimination of Trichuris trichiura","volume":"1","author":"Turner","year":"2016","journal-title":"Parasite Epidemiol Control"},{"key":"2021091515515813900_CIT0043","doi-asserted-by":"crossref","first-page":"e0008033","DOI":"10.1371\/journal.pntd.0008033","article-title":"Modelling for policy: the five principles of the Neglected Tropical Diseases Modelling Consortium","volume":"14","author":"Behrend","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"2021091515515813900_CIT0044","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.pt.2014.10.001","article-title":"Neglected tools for neglected diseases: mathematical models in economic evaluations","volume":"30","author":"Turner","year":"2014","journal-title":"Trends Parasitol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciab350\/38856502\/ciab350.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/6\/e1391\/40392416\/ciab350.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/6\/e1391\/40392416\/ciab350.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T16:03:13Z","timestamp":1631721793000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/6\/e1391\/6248449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,23]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,4,23]]},"published-print":{"date-parts":[[2021,9,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciab350","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,15]]},"published":{"date-parts":[[2021,4,23]]}}}